



GLOBAL JOURNAL OF MEDICAL RESEARCH: E
GYNECOLOGY AND OBSTETRICS
Volume 15 Issue 4 Version 1.0 Year 2015
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Ewing Sarcoma of Ovary-An Unusual Presentation

By Humera Mahmood, Mohammad Faheem, Sana Mahmood & Sarosh Arif

Oncology & Radiotherapy Institute (NORI) Islamabad, Pakistan

Abstract- Ewing's sarcoma generally arises from bones and soft tissues. Primitive neuroectodermal tumor (PNET) and Ewing sarcoma constitute Ewing family of tumors. In International literature there have been rare reports of Ewing's sarcoma as either primary tumor of ovary or as metastatic disease involving ovary. No such case has yet been reported in Pakistan. Here a case is being presented who was diagnosed as Ewing's sarcoma of ovary. Workup showed no involvement of the bones.

Keywords: ewing's sarcoma, PNET, ovary.

GJMR-E Classification : NLMC Code: WP 320



Strictly as per the compliance and regulations of:



© 2015. Humera Mahmood, Mohammad Faheem, Sana Mahmood & Sarosh Arif. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License <http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ewing Sarcoma of Ovary-An Unusual Presentation

Humera Mahmood ^α, Mohammad Faheem ^σ, Sana Mahmood ^ρ & Sarosh Arif ^ω

Abstract- Ewing's sarcoma generally arises from bones and soft tissues. Primitive neuroectodermal tumor (PNET) and Ewing sarcoma constitute Ewing family of tumors. In International literature there have been rare reports of Ewing's sarcoma as either primary tumor of ovary or as metastatic disease involving ovary. No such case has yet been reported in Pakistan. Here a case is being presented who was diagnosed as Ewing's sarcoma of ovary. Workup showed no involvement of the bones.

Keywords: ewing's sarcoma, PNET, ovary.

I. INTRODUCTION

Ewing's sarcoma is malignant round blue cell tumor which primarily arises from bones involving pelvis, femur, tibia, humerus and clavicle. Patients affected are commonly in their second decade of life. The definitive diagnosis is based on histomorphology, immunohistochemistry and molecular pathology. The pathologic differential diagnosis is the grouping of small round cell tumors which include lymphoma, alveolar rhabdomyosarcoma and others. Ewing's sarcoma typically has clear cytoplasm on H & E staining due to glycogen. Positive PAS staining proves the presence of glycogen. The characteristic immunostain is CD99 which diffusely marks cell membrane. The morphologic and immunohistochemical characteristics are corroborated with chromosomal translocations of which t(11;22)(q24;q12) is the commonest present in about 90% of Ewing's sarcomas¹. Ovary is very rare site to give origin to Ewing's sarcoma. Few cases of ovarian Ewing's sarcoma have been reported in literature mainly affecting females 18-30 years of age and in all these cases diagnosis was made with the help of immunohistochemistry. Cases of Ewing's sarcoma of uterus, vagina and vulva have also been reported². We are reporting a case of 30year old lady who was diagnosed as having Ewing's sarcoma of ovary.

II. CASE REPORT

A 30 year old, premenopausal lady having 4 children with last child birth 4 years back and no significant family history presented at NORI Islamabad on 19th February 2014. She had already undergone

exploratory laparotomy on 12th December 2013. She presented to gynecologist with complaint of pain lower abdomen. Her Abdominal USG was done on 8th December 2013 which showed a large solid mobile mass in mid pelvis. The mass was not showing any relationship with major abdominal/pelvic organs. This was then followed by CT scan which showed a large well defined, smooth walled, complex soft tissue attenuation mass measuring 7.7x9.1 cm. The exact site of origin was difficult to ascertain on CT scan but it was probably in mesenteric fat. The lesion was mostly solid and differentials could be tumor of neural origin, lymphoma, GIST or carcinoid mass. There was additional finding of a suspicious mass in pelvis which was reported as either an adnexal mass or a nodal deposit (Fig A and B). This was then followed by exploratory laparotomy. CT scan report was not clear regarding the origin of pelvic mass. There were two masses peroperatively. One of the masses was measuring 4x4 cm and was related to posterior surface of uterus. The other mass measured 8x8 cm and was attached to fallopian tube. Excision of masses was done and histopathology showed Granulosa cell tumor of ovarian origin. Slide review was advised due to unusual presentation that was not in accordance with Granulosa cell tumor. Histopathology reviewed showed Ewing Sarcoma. Immunohistochemistry demonstrated positivity of CD99 and NSE thus endorsing the diagnosis of Ewing Sarcoma. Postoperative CT scan was done that showed minimal pelvic ascites. She was planned for chemotherapy but our patient was then lost to follow up. She presented again to our hospital in July 2014 with complaint of pain abdomen. On examination there was a huge mass palpable in lower abdomen lower limit of which was not reachable. On pervaginal examination a mass could be felt outside vagina in relation to its posterior wall. CT scan was repeated that showed a large lobulated mesenteric mass and a pelvic mass with rectal wall thickness (Fig C and D). The case was discussed in MDM and it was decided to give her chemotherapy followed by evaluation for surgery. Vincristine, Doxorubicin and Cyclophosphamide were started alternating with Ifosfamide and Etoposide. Interval assessment was done. Although there was reduction in size of mesenteric and pelvic mass,(Fig E and F) however, surgery was still not possible due to indistinct fat planes with rectum. Chemotherapy was continued till 17 cycles. Doxorubicin was replaced with Dactinomycin after 5 cycles of Doxorubicin. Recent CT scan showed further reduction in size of pelvic mass

Author α: (Corresponding Author) Consultant Oncologist, Department of Oncology, Nuclear Medicine, Oncology & Radiotherapy Institute (NORI) Islamabad. e-mail: hmhfaheem02@gmail.com

Author σ: Head Oncology, Nuclear Medicine, Oncology & Radiotherapy Institute (NORI) Islamabad.

Author ρ ω: Resident Oncology, Nuclear Medicine, Oncology & Radiotherapy Institute (NORI) Islamabad.

and resolution of mesenteric mass. Fat planes with rectum became distinct. Currently, she has been referred for surgery after discussion in MDM.


III. DISCUSSION

Formerly thought to be dissimilar Ewing sarcoma and PNET are now considered to be same tumors that demonstrate variable degree of neuroectodermal differentiation. Ewing sarcoma lacks neuroectodermal differentiation whereas PNET expresses neuroectodermal differentiation when evaluated either by microscopy or IHC³. Extraosseous Ewing Sarcoma is a rare entity and that of female genital tract is extremely uncommon. The commonest site of PNET in female genital tract is ovary followed by uterus. The paucity of the disease can result in diagnostic dilemmas⁴. Our patient was also initially misdiagnosed as a case of Granulosa cell tumor of ovary. In her case not only histopathology was incorrect but also imaging studies were misleading. The site of origin and accurate diagnosis was determined only after review of histopathology and immunohistochemistry. Had the patient been discussed in multidisciplinary meeting prior to embarking on surgery, in view of extensive disease she could have been advised neoadjuvant chemotherapy after guided biopsy. Another appropriate approach might have been diagnostic laparoscopy. Ovarian PNETs are very aggressive tumors and are associated with extremely poor prognosis due to high incidence of metastatic disease. Median survival ranges from 10.8 months to 3 years. The prognosis of patients presenting with localized tumors has improved in recent years by means of multimodality treatment such as surgery, radiation and chemotherapy. Chemotherapeutic agents frequently used are vincristine, doxorubicin and cyclophosphamide alternating with

lfsosamide and doxorubicin⁵. Although optimal debulking was done in this particular case as evident by postoperative CT scan but she didn't come for adjuvant treatment resulting in local recurrence within 4-5 months of surgery. In a case report by Anfinan et al local recurrence in 31 years old female was seen during adjuvant chemotherapy with vincristine, doxorubicin and lfsosamide alternating with vincristine, adriamycin and lfsosamide. Cases of Ewing sarcoma already reported in literature were in 18 to 30 years age group² and our patient was also 30 years old. This shows that patients to be affected with ovarian Ewing sarcoma are relatively young. A number of chromosomal abnormalities are associated with PNET/Ewing sarcoma including deletion of Retinoblastoma gene, ras homologue member 1 and overexpression of N-myc, fas ligand, tumor necrosis factor and epidermal growth factor receptor. These factors may perhaps be responsible for aggressive nature of these tumors⁶. Due to non availability in Pakistan chromosomal abnormalities were not studied in this patient but CD99 and NSE were strongly positive on Immunohistochemistry. Our patient has responded well to chemotherapy, whether this translates into better survival warrants further follow up.

IV. CONCLUSION

Although rare but Ewing sarcoma of ovary should be kept in differential diagnosis particularly in young patients having unusual presentation. Immunohistochemical markers should be applied for proper diagnosis. Here also comes importance of multidisciplinary meetings. Strong coordination is required among oncologists, gynecologists, radiologists and pathologists before putting the patient on any treatment modality.






Fig A and B : Pre operative CT scan showing mesenteric mass and suspicious mass in pelvis.

Fig C and D : Pre chemotherapy CT scan showing recurrent mass in mesentery and huge pelvic mass.

Fig E and F : CT scan done after 6 cycles for interval assessment showing regression of masses.

Fig G and H : CT scan done after completion of chemotherapy showing resolution of mesenteric mass and further regression of pelvic mass

REFERENCES RÉFÉRENCES REFERENCIAS

1. Richard J, Steven GD, Daphne AHK. Sarcomas of Bone. In: Devita VT, Lawrence TS, Rosenberg SA, editors. *Cancer Principles & Practice of Oncology*. 10th edition. Wolters Kluwer Lippincott: Williams and Wilkins; 2015. pp. 1293–1311.
2. Giuseppe L, Leonardo R, Edoardo DN, Anna MC, Salvatore AM, Mario V, et al. Conservative treatment of Ewing's sarcoma of uterus in young women. *Case Rep Obstet Gynecol*. 2015; 2015: <http://dx.doi.org/10.1155/2015/871821>.
3. YIP CM, HSU SS, Chang NJ, Wang JS, Liao WC, Chen JY, et al. Primary vaginal extraosseous ewing sarcoma/ primitive neuroectodermal tumor with cranial metastasis. *J Chin Med Assoc*. 2009; 72(6): 332-5.
4. Mashriqi N, Gujjarlapudi JK, Sidhy J, Zur M, Yalamanchili M. Ewing's sarcoma of cervix a diagnostic dilemma: a case report and review of literature. *J Med Case Rep*. 2015; 9(1): 225. DOI 10.1186/s13256-015-0733-2.
5. Kuk JY, Yoon SY, Kim MJ, Lee JW, Kim BG, Bae DS. A case of primitive neuroectodermal tumor of the ovary. *Korean J Obstet Gynecol*. 2012; 55(10): 777-81.
6. Anfinan NM, Sait KH, Al-Maghrabi JA. Primitive neuroectodermal tumor the ovary. *Saudi Med J*. 2008; 29(3): 444-6.